Anna M Georgiopoulos
Overview
Explore the profile of Anna M Georgiopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Richards C, Friedman D, Pinsky H, Gootkind E, Lee H, Yonker L, et al.
Pediatr Pulmonol
. 2023 Jun;
58(9):2535-2542.
PMID: 37294071
Background: International consensus statements on depression and anxiety in adolescents and adults with cystic fibrosis (awCF) recommend assessment for comorbid substance misuse. However, at CF centers, the frequency and impact...
12.
Bathgate C, Muther E, Georgiopoulos A, Smith B, Tillman L, Graziano S, et al.
Pediatr Pulmonol
. 2023 Jun;
58(9):2469-2477.
PMID: 37265418
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with unprecedented clinical improvements, transforming the management of cystic fibrosis (CF). However, side effects with implications for safety and well-being have been reported, including...
13.
Verkleij M, Georgiopoulos A, Barendrecht H, Friedman D
Pediatr Pulmonol
. 2023 May;
58(7):2094-2103.
PMID: 37144856
Background: eHealth CF-CBT is the first digital mental health intervention for depression/anxiety in adults with cystic fibrosis (awCF); an 8-session therapist-guided internet-delivered program that was developed in English and Dutch...
14.
Baroud E, Chaudhary N, Georgiopoulos A
Pediatr Pulmonol
. 2023 Apr;
58(7):1920-1930.
PMID: 37036050
Introduction: Reports of neuropsychiatric symptoms proximal to cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation are emerging, but their prevalence and management remain poorly characterized. Methods: Retrospective chart review was...
15.
Quittner A, Barker D, Graziano S, Georgiopoulos A, Muther E, Verkleij M, et al.
Pediatr Pulmonol
. 2023 Apr;
58(6):1768-1776.
PMID: 37014155
Objectives: The CF Foundation sponsored competitive awards for Mental Health Coordinators (MHCs) from 2016 to 2018 to implement the international guidelines for mental health screening and treatment in US CF...
16.
Basile M, Dhingra L, DiFiglia S, Polo J, Portenoy R, Wang J, et al.
J Patient Exp
. 2023 Mar;
10:23743735231161486.
PMID: 36936380
To prevent or mitigate chronic illness burden, people with cystic fibrosis (pwCF) and their family caregivers need primary (generalist-level) palliative care from the time of diagnosis forward. We used qualitative...
17.
Bathgate C, Hjelm M, Filigno S, Smith B, Georgiopoulos A
Clin Chest Med
. 2022 Nov;
43(4):791-810.
PMID: 36344081
This article is intended for use among all cystic fibrosis care team members. It covers common mental health concerns and their unique presentations in persons with cystic fibrosis (pwCF) in...
18.
Friedman D, Kaskas M, Quittner A, Smith B, Georgiopoulos A
Front Psychol
. 2022 Oct;
13:937189.
PMID: 36275208
Individuals with cystic fibrosis (CF) are at high risk for depression and anxiety, with negative consequences for health and quality of life. Cystic Fibrosis Foundation/European Cystic Fibrosis Society guidelines recommend...
19.
Landau E, Verkleij M, Graziano S, Quittner A, Georgiopoulos A, Smith B, et al.
Respir Med
. 2022 Sep;
202:106955.
PMID: 36084563
No abstract available.
20.
Friedman D, Smith B, Bruce A, Schwartz C, Lee H, Pinsky H, et al.
Pediatr Pulmonol
. 2022 Aug;
57(11):2781-2790.
PMID: 35931665
Background: A cystic fibrosis (CF)-specific cognitive-behavioral therapy intervention (CF-CBT) was developed in partnership with the CF community to advance preventive mental health care. Multidisciplinary providers across three centers were trained...